Atlas Trials

Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Clinical trial NCT06164327 · UNKNOWN

Trial details

NCT number
NCT06164327
Sponsor
BeBetter Med Inc
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Start date
2023-12-01
Primary completion
2025-10-31
Enrollment
75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.